Conventional wisdom suggests that a high level of the protein prostate specific antigen (PSA) in men with prostate cancer means a poor prognosis. However, this may not always be the case in men with a particular subtype of prostate cancer, according to a new study from Weill Cornell Medicine and NewYork-Presbyterian researchers.
New molecules engineered by Weill Cornell Medicine researchers can enable rapid, direct “editing” of genes in a wide range of cell types, creating an array of research and therapeutic possibilities.
Gene mutations detected in blood may predict risk of one of the most common forms of adult leukemia a decade before patients are diagnosed with the disease, according to a new study by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Weill Cornell Medicine, in collaboration with Columbia University Irving Medical Center and NewYork-Presbyterian, has been awarded a $900,000 grant from the U.S. Department of Defense (DoD) to conduct prostate cancer clinical trials.
An enzyme implicated in autoimmune diseases and viral infections also regulates radiation therapy’s ability to trigger an immune response against cancer.
A newly discovered type of genetic mutation that occurs frequently in cancer cells may provide clues about the disease’s origins and offer new therapeutic targets.
Dr. Virginia Pascual, a renowned physician-scientist specializing in pediatric rheumatology, has been appointed the founding Gale and Ira Drukier Director of the Gale and Ira Drukier Institute for Children’s Health.
NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine are among the nation's top cancer centers endorsing HPV vaccination for cancer prevention.
